This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AFFX Affymetrix (AFFX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Affymetrix Stock (NASDAQ:AFFX) 30 days 90 days 365 days Advanced Chart Get Affymetrix alerts:Sign Up Key Stats Today's Range$14.01▼$14.0150-Day Range N/A52-Week Range$8.28▼$16.15VolumeN/AAverage Volume3.49 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia. Read More Receive AFFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affymetrix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AFFX Stock News HeadlinesAffymetrix Reaches New 52-Week High (AFFX)April 4, 2023 | thestreet.comThermo Fisher Can Afford More Deals After Affymetrix BuyFebruary 21, 2023 | thestreet.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 28 at 2:00 AM | Brownstone Research (Ad)Affymetrix (AFFX) Stock Drops After Rejecting Origin Technologies Takeover BidJanuary 2, 2023 | thestreet.com'Mad Money' Lightning Round: A Group to AvoidMarch 1, 2022 | thestreet.comThermos Fisher (TMO) Stock Closed Up on Affymetrix AcquisitionJanuary 19, 2022 | thestreet.comSee More Headlines AFFX Stock Analysis - Frequently Asked Questions How were Affymetrix's earnings last quarter? Affymetrix Inc (NASDAQ:AFFX) posted its quarterly earnings results on Wednesday, February, 17th. The scientific and technical instruments company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by $0.02. The scientific and technical instruments company had revenue of $95.60 million for the quarter, compared to analyst estimates of $93.29 million. What other stocks do shareholders of Affymetrix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affymetrix investors own include Orchid Island Capital (ORC), XOMA Royalty (xoma), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), Meta Platforms (META), ACADIA Pharmaceuticals (ACAD) and Intel (INTC). Company Calendar Last Earnings2/17/2016Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:AFFX CIK913077 Webwww.affymetrix.com Phone+1-408-7315000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AFFX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affymetrix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Affymetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.